FDA Releases Final Guidance for Special Protocol Assessments

Drug Industry Daily
A A
The FDA finalized guidance on its special protocol assessment (SPA) program that offers sponsors an advanced declaration from the agency that their trial designs, clinical endpoints, and statistical analyses are acceptable.

To View This Article:

Login

Subscribe To Drug Industry Daily